Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TRAVERE THERAPEUTICS, INC.

(TVTX)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
21.88 USD   +0.23%
01/26Insider Sell: Travere Therapeutics
MT
01/20U.S. asks judge to hold Shkreli in contempt for allegedly flouting pharma industry ban
RE
01/13Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Wells Fargo Starts Travere Therapeutics at Overweight With $28 Price Target

12/05/2022 | 08:25am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
TRAVERE THERAPEUTICS, INC. 0.23% 21.88 Delayed Quote.4.04%
WELLS FARGO & COMPANY 0.68% 46.12 Delayed Quote.11.70%
All news about TRAVERE THERAPEUTICS, INC.
01/26Insider Sell: Travere Therapeutics
MT
01/20U.S. asks judge to hold Shkreli in contempt for allegedly flouting pharma industry ban
RE
01/13Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
AQ
01/12TravereáTherapeutics ReportsáInducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
01/12TravereáTherapeutics ReportsáInducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
01/12Transcript : Travere Therapeutics, Inc. Presents at 41st Annual J.P. Morgan H..
CI
01/11Piper Sandler Adjusts Price Target on Travere Therapeutics to $42 From $38, Keeps Overw..
MT
01/09Travere Therapeutics : Corporate Overview – January 2023
PU
01/09Travere Therapeutics Sees Lower Full-Year 2022 Revenue
MT
01/09Travere Therapeutics Provides Corporate Update and 2023 Outlook
GL
More news
Analyst Recommendations on TRAVERE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 211 M - -
Net income 2022 -277 M - -
Net cash 2022 67,5 M - -
P/E ratio 2022 -5,04x
Yield 2022 -
Capitalization 1 404 M 1 404 M -
EV / Sales 2022 6,33x
EV / Sales 2023 4,60x
Nbr of Employees 310
Free-Float 98,7%
Chart TRAVERE THERAPEUTICS, INC.
Duration : Period :
Travere Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRAVERE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 21,88 $
Average target price 32,25 $
Spread / Average Target 47,4%
EPS Revisions
Managers and Directors
Eric M. Dube President, Chief Executive Officer & Director
Chris Cline Chief Financial Officer
Gary A. Lyons Chairman
William E. Rote Senior VP, Head-Research & Development
Jula Inrig Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TRAVERE THERAPEUTICS, INC.4.04%1 404
VERTEX PHARMACEUTICALS11.16%82 513
REGENERON PHARMACEUTICALS, INC.2.88%79 336
WUXI APPTEC CO., LTD.20.37%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008